Published in Nucl Med Commun on October 01, 1985
CD55 is over-expressed in the tumour environment. Br J Cancer (2001) 1.27
Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals. Dalton Trans (2011) 1.11
A prospective study of the use of 111In-labelled monoclonal antibody against carcino-embryonic antigen in colorectal cancer and of some biological factors affecting its uptake. Int J Colorectal Dis (1989) 0.95
MRI/SPECT/Fluorescent Tri-Modal Probe for Evaluating the Homing and Therapeutic Efficacy of Transplanted Mesenchymal Stem Cells in a Rat Ischemic Stroke Model. Adv Funct Mater (2015) 0.90
The localization of anti-tumour monoclonal antibodies in colorectal cancer. Ann R Coll Surg Engl (1986) 0.75
Patterns of reactivity of the monoclonal antibody 791T/36 with different tumour metastases in the liver. Br J Cancer (1986) 0.75
Delay in diagnosis and treatment of symptomatic colorectal cancer. Lancet (1979) 4.91
Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. Lancet (1989) 4.72
A classification of fistula-in-ano. Br J Surg (1976) 4.09
Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol (1972) 4.04
Controlled trial of faecal occult blood testing in the detection of colorectal cancer. Lancet (1983) 3.99
Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut (1988) 3.14
Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol (1991) 2.83
The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut (1999) 2.53
Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut (2002) 2.50
Surgical emergencies and manpower. Ann R Coll Surg Engl (1984) 2.48
Study of large bowel peristalsis. Gut (1968) 2.34
A phase I/II study of trichosanthin treatment of HIV disease. AIDS (1990) 2.26
Demonstration of tumour-specific humoral antibody against aminoazo dye-induced rat hepatomata. Br J Cancer (1967) 2.23
The influence of tumour cell DNA abnormalities on survival in colorectal cancer. Br J Surg (1985) 2.20
Ambulatory monitoring of oesophageal pH in reflux oesophagitis using a portable radiotelemetry system. Gut (1982) 2.19
Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br J Surg (1994) 2.18
The results of 1115 patients with colorectal cancer treated over an 8-year period in a single hospital. Eur J Surg Oncol (1985) 2.03
Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut (1992) 1.96
Tumour-specific immunity against spontaneous rat tumours. Int J Cancer (1966) 1.83
Demonstration of cell-surface antigens on chemically induced tumors. Ann N Y Acad Sci (1971) 1.78
A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology (1984) 1.72
Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet (1982) 1.71
Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa. J Pathol (1996) 1.70
Cost-effective screening strategies for colorectal cancer. J Public Health Med (1992) 1.67
Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut (2011) 1.67
Risks, costs, and compliance limit colorectal adenoma surveillance: lessons from a randomised trial. Gut (2001) 1.63
Comparison of lateral thermal spread using monopolar and bipolar diathermy, the Harmonic Scalpel and the Ligasure. Br J Surg (2010) 1.62
Tumour-specific antigenicity of aminoazo-dye-induced rat hepatomas. Int J Cancer (1967) 1.62
Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer (1981) 1.61
Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas. Rev Eur Etud Clin Biol (1971) 1.60
Clinical and economic consequences of wound sepsis after appendicectomy and their modification by metronidazole or povidone iodine. Lancet (1981) 1.57
Physical factors in the stimulation of colonic peristalsis. Gut (1970) 1.57
Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer (2001) 1.56
Hypertension and impaired renal function accompany juvenile obesity: the effect of prenatal diet. Kidney Int (2007) 1.56
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol (1995) 1.53
Factors affecting compliance with screening for colorectal cancer. Community Med (1984) 1.52
Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ (1998) 1.51
BCG immunotherapy of a rat sarcoma. Br J Cancer (1973) 1.50
Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumour-bearer serum, and solubilized hepatoma antigen. Int J Cancer (1973) 1.49
Screening for colorectal cancer with an immunological faecal occult blood test: 2-year follow-up. Br J Surg (1996) 1.49
BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer (1973) 1.49
Cellular and humoral immunity to rat hepatoma-specific antigens correlated with tumour status. Int J Cancer (1973) 1.48
Screening for symptomless colorectal cancer by testing for occult blood in general practice. Lancet (1980) 1.48
Clinical and radiographic features of simple and hydatid cysts of the liver. Br J Surg (1986) 1.47
A frequency-duration index (FDI) for the evaluation of ambulatory recordings of gastro-oesophageal reflux. Br J Surg (1984) 1.45
Bile reflux in columnar-lined Barrett's oesophagus. Ann R Coll Surg Engl (1993) 1.44
Screening and the costs of treating colorectal cancer. Br J Cancer (1993) 1.44
Acute non-tuberculous psoas abscess. Report of 10 cases and review of the literature. Br J Surg (1970) 1.42
Solubilization of tumour-specific antigen from plasma membrane of an aminoazo-dye-induced rat hepatoma. Clin Exp Immunol (1972) 1.41
Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer (1986) 1.40
Flexible fiberoptic sigmoidoscopy and double-contrast barium-enema examination in the identification of adenomas and carcinoma of the colon. Dis Colon Rectum (1983) 1.39
Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc Natl Acad Sci U S A (1996) 1.39
Predeposit autologous blood transfusion in patients with colorectal cancer: a feasibility study. Br J Surg (1992) 1.39
Monoclonal antigranulocyte antibody imaging in inflammatory bowel disease: a preliminary report. Nucl Med Commun (1992) 1.39
111In-labelled leucocyte imaging in vascular graft infection. Br J Surg (1989) 1.39
Clinical signs in scaphoid fractures. J Hand Surg Br (1994) 1.37
Early diagnosis of colorectal cancer: a review. J R Soc Med (1984) 1.37
Studies on the immunobiology of rnu/rnu "nude" rats with congenital aplasia of the thymus. Eur J Immunol (1980) 1.36
Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro. Int J Cancer (1983) 1.35
Subcuticular suturing after appendicectomy. Lancet (1977) 1.32
Immunological aspects of chemical carcinogenesis. Adv Cancer Res (1973) 1.31
Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm (1999) 1.30
Neoantigens on spontaneous and carcinogen-induced rat tumors defined by in vitro lymphocytotoxicity assays. Int J Cancer (1974) 1.30
Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test. Int J Epidemiol (1999) 1.29
Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed) (1985) 1.29
An evaluation of flexible fibreoptic sigmoidoscopy. Br Med J (Clin Res Ed) (1981) 1.28
BCG immunotherapy of rat tumours in athymic nude mice. Nature (1975) 1.27
Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res (1995) 1.27
Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol (1990) 1.27
Phenotype of rat natural killer cells defined by monoclonal antibodies marking rat lymphocyte subsets. Immunology (1982) 1.25
Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Br J Cancer (1987) 1.23
Gastrointestinal intraluminal pH in normal subjects and those with colorectal adenoma or carcinoma. Gut (1990) 1.22
The action of sennosides and related compounds on human colon and rectum. Gut (1970) 1.22
Comparison of rigid and flexible fibreoptic sigmoidoscopy with double contrast barium enemas. Br J Surg (1982) 1.21
Isolation of membrane-associated tumour-specific antigen from an aminoazo-dye-induced rat hepatoma. Int J Cancer (1969) 1.21
Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg (1997) 1.21
Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol (1995) 1.21
Use of glyceryl trinitrate ointment in the treatment of anal fissure. Br J Surg (1996) 1.20
Transanal endoscopic microsurgery--initial experience from three centres in the United Kingdom. Br J Surg (1996) 1.20
Detection and isolation of tumour-specific antigen associated with a spontaneously arising rat mammary carcinoma. Int J Cancer (1970) 1.20
Immunogenic properties of rat hepatoma subcellular fractions. Br J Cancer (1974) 1.20
Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing. Br J Surg (1982) 1.20
Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus. Gut (1992) 1.20